iCAD Among the First to Validate its AI Cancer Detection Solutions with the NVIDIA AI Enterprise Software Suite
March 02, 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., March 02, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it is...
iCAD to Present at the 42nd Annual Cowen Health Care Conference
March 01, 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., March 01, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the...
iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2021
February 28, 2022 16:05 ET
|
iCAD, Inc.
Launched ProFound AI® Risk, the world’s first clinical decision support tool for short term breast cancer risk estimation Demonstrated compelling survival data for the use of Xoft® Brain IORT in...
iCAD to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28
February 14, 2022 16:05 ET
|
iCAD, Inc.
NASHUA, N.H., Feb. 14, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it...
iCAD to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 08, 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., Feb. 08, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company...
iCAD’s Breast AI Platform Earns U.S. Department of Defense Authorization to Operate
January 24, 2022 14:25 ET
|
iCAD, Inc.
NASHUA, N.H., Jan. 24, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the...
iCAD Announces the Appointment of New Members to its Board of Directors
January 11, 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., Jan. 11, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced today it has...
iCAD Announces Estimated Q4 and Fiscal Year 2021 Revenues
January 04, 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., Jan. 04, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, reported select...
iCAD to Participate at the 11th Annual LifeSci Partners Virtual Corporate Access Event
December 23, 2021 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., Dec. 23, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it...
First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States
December 14, 2021 08:00 ET
|
iCAD, Inc.
Treatment marks initiation of international multicenter trial evaluating targeted radiation therapy and bevacizumab for the treatment of the most common and aggressive type of malignant brain tumor ...